Argent Biopharma Ltd (ASX: RGT) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Argent Biopharma Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Argent Biopharma Ltd (ASX: RGT)
Latest News
⏸️ Investing
Why BOD Australia Ltd jumped 40% in a day
⏸️ Investing
Why these 4 ASX shares have dropped lower today
⏸️ Investing
Here are 2017's best performing ASX pot stocks
⏸️ Investing
Are the ASX pot stocks running out of puff?
⏸️ Investing
Medical marijuana stocks are smoking hot right now
⏸️ Investing
Why MGC Pharmaceuticals Ltd shares jumped 11% higher
⏸️ Investing
What's the best ASX pot stock to buy?
⏸️ Investing
Australian pot stocks: November update
⏸️ Investing
MGC Pharmaceuticals Ltd shares have doubled in value in a month
⏸️ Investing
Pot stocks are flying high: Here's what you need to know
⏸️ Investing
Why Auscann Group Holdings Ltd shares are up 29% this week
⏸️ Investing
MGC Pharmaceuticals Ltd shares surge higher on sales agreement
RGT ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About Argent Biopharma Ltd
MGC Pharmaceuticals Ltd. engages in the production of medical marijuana. Its Endocannabinoid system covers all cells and nerves; it is the messenger of information flowing between immune system and the central nervous system. The company was founded by Nativ Segev on October 21, 2005 and is headquartered in Perth, Australia.
RGT Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
24 Dec 2024 | $0.15 | $-0.01 | -6.45% | 4,289 | $0.16 | $0.16 | $0.15 |
23 Dec 2024 | $0.16 | $0.00 | 0.00% | 155 | $0.16 | $0.16 | $0.16 |
20 Dec 2024 | $0.16 | $-0.02 | -11.76% | 56,564 | $0.16 | $0.16 | $0.16 |
19 Dec 2024 | $0.17 | $0.00 | 0.00% | 2,788 | $0.17 | $0.17 | $0.17 |
18 Dec 2024 | $0.17 | $0.00 | 0.00% | 85,389 | $0.17 | $0.18 | $0.17 |
17 Dec 2024 | $0.17 | $-0.01 | -5.56% | 37,648 | $0.18 | $0.18 | $0.17 |
16 Dec 2024 | $0.18 | $0.01 | 5.71% | 33,084 | $0.18 | $0.18 | $0.18 |
13 Dec 2024 | $0.18 | $-0.02 | -10.26% | 63,991 | $0.19 | $0.19 | $0.18 |
12 Dec 2024 | $0.20 | $-0.01 | -5.00% | 21,673 | $0.20 | $0.20 | $0.19 |
11 Dec 2024 | $0.20 | $0.01 | 5.26% | 4,935 | $0.20 | $0.20 | $0.20 |
10 Dec 2024 | $0.19 | $-0.01 | -5.00% | 13,544 | $0.20 | $0.20 | $0.19 |
09 Dec 2024 | $0.20 | $0.00 | 0.00% | 1,339 | $0.20 | $0.20 | $0.20 |
06 Dec 2024 | $0.21 | $-0.02 | -9.09% | 146 | $0.21 | $0.21 | $0.21 |
05 Dec 2024 | $0.22 | $0.01 | 4.65% | 2,461 | $0.22 | $0.23 | $0.22 |
04 Dec 2024 | $0.22 | $-0.03 | -12.50% | 3,863 | $0.22 | $0.22 | $0.21 |
03 Dec 2024 | $0.24 | $-0.01 | -4.00% | 2,640 | $0.24 | $0.24 | $0.24 |
02 Dec 2024 | $0.25 | $-0.02 | -7.41% | 8,705 | $0.27 | $0.27 | $0.25 |
29 Nov 2024 | $0.27 | $0.02 | 8.00% | 2,100 | $0.25 | $0.27 | $0.25 |
28 Nov 2024 | $0.25 | $0.00 | 0.00% | 6,220 | $0.26 | $0.26 | $0.25 |
27 Nov 2024 | $0.25 | $0.01 | 4.17% | 19,907 | $0.26 | $0.26 | $0.25 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
15 Oct 2024 | Roby Zomer | Buy | 4,000,000 | $1,640,000 |
As advised by the company.
|
10 Sep 2024 | Roby Zomer | Buy | 1,258,500 | $503,400 |
Off-market trade.
|
28 Mar 2024 | Layton Mills | Issued | 120,000 | $49,200 |
Issue of options.
|
28 Mar 2024 | Daniel Robinson | Issued | 120,000 | $49,200 |
Issue of options.
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Mr Layton Patrick Mills | Non-Executive Director | Jun 2023 |
Mr. Mills is an experienced life-sciences executive, having worked in the biotechnology and life sciences industries for over 15 years, developing experience across human and animal health in pharmaceutical and consumer healthcare. Mr Mills is also the founder and Managing Director of Subgenix Lifesciences, an early-stage biotechnology Company using conventional drug development strategies to unlock the broader therapeutic potential of psychedelic compounds for rare and underserved health needs. He has international business experience having been involved in corporate business activities across Europe, Asia and North America, including government-led trade incentives with the Canberra Business Chamber.
|
Mr Brett Anthony Mitchell | Executive ChairmanExecutive Director | Apr 2013 |
Mr Mitchell has over 25 years of experience in the venture capital, equity capital markets, technology and resources sectors. He has been involved in the founding, financing and management of both private and publicly listed companies, and was instrumental in the successful LSE listing for MGC Pharma in February 2021.
|
Mr Daniel Robinson | Non-Executive Director | Dec 2023 |
Mr Robinson has been appointed as a Non-Executive Director of the Company effective immediately. Mr Robinson has over 20 years of experience in a broad range of corporate roles across stockbroking, corporate advisory, investor relations and governance. He is an experienced Company Secretary and Director of both private and listed companies. Additionally, Mr Robinson is a Member of the Australian Institute of Company Directors.
|
Mr Nativ Segev | Non-Executive Director | Feb 2016 |
Mr Segev has over 10 years of experience in implementation, legislation and lobbying in the global Medical Cannabis industry, combined with over 15 years of experience in diverse executive roles.
|
Mr Roby Reuven Zomer | Chief Executive OfficerManaging Director | Feb 2016 |
Mr Zomer is an executive with experience in the biopharmaceutical and biotech industries. As the CEO of the company, Roby has demonstrated has driven strategic growth, managed financial operations, and ensured compliance with industry-specific standards. He also served as the Chairman of the Board for Graft Polymer, overseeing the implementation of advanced polymer solutions in the Biotech, Automotive and Recycling sectors. Roby's entrepreneurial background includes founding and leading Green City Urban Recycling, a pioneering Israeli company focused on biofuel production. His innovative work in this field contributed to national energy independence initiatives and led to the company's acquisition by Rafael Advanced Defense Systems. With an industrial engineering and management foundation, Roby Zomer brings a blend of technical and strategic skills to his professional endeavors.
|
Mr Rowan Harland | Company Secretary | Mar 2023 |
-
|
Rowan Harland | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
Oak Capital Partners Llc | 8,370,718 | 17.29% |
Group Capital Llc | 3,913,812 | 8.09% |
David Safren | 3,405,016 | 7.03% |
Citicorp Nominees Pty Limited | 2,301,084 | 4.75% |
Shlomie Bierman | 2,230,874 | 4.61% |
Computershare Clearing Pty Ltd <Ccnl Di A/C> | 2,099,936 | 4.34% |
Isamar Margareten | 1,956,906 | 4.04% |
Mr Shachar Shimony | 1,933,000 | 3.99% |
Yaakov Safren | 1,643,802 | 3.40% |
Jacob Goldstein | 1,623,072 | 3.35% |
Yoram Drucker | 1,604,664 | 3.32% |
Yosef Safren | 1,565,526 | 3.23% |
Shalom Safren | 1,448,112 | 2.99% |
Bioheka Limited | 1,258,500 | 2.60% |
Mrs Yifat Steuer | 1,117,194 | 2.31% |
Eliron Yaron | 750,000 | 1.55% |
A1 Invest Llc | 625,000 | 1.29% |
Mr Itay David Nissim | 600,000 | 1.24% |
Mr Amir Polak | 592,626 | 1.22% |
Joseph Schwartz | 547,934 | 1.14% |